Retatrutide 30mg

Description

Strength: 30mg
CAS: 2381089-83-2
Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular weight: 4845.444 g/mol
Peptide Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
Synonyms: Retatrutide acetate, LY3437943
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

Retatrutide 30mg is a research peptide from Novera Compounds (United States), supplied as a lyophilized 30mg vial requiring reconstitution with BAC water (bacteriostatic water) prior to laboratory use. It is a triple-receptor agonist that activates the glucagon, GLP-1, and GIP receptors simultaneously, making it a subject of ongoing research on weight loss and metabolism. Professionals looking to buy Retatrutide 30mg for permitted research purposes can contact the Maylips support team for sourcing guidance and documentation. This product is intended strictly for in vitro research ONLY and is NOT approved for human use, clinical application, or human consumption.

Product Specifications

• Strength: 30 mg per vial
• Active Compound: Retatrutide peptide
• Form: Lyophilized powder
• Reconstitution: Requires BAC water (bacteriostatic water)
• Manufacturer: Novera Compounds
• Country of Origin: United States
• Brand: Novera
• Intended Use: Research and in vitro studies only. NOT for human consumption
• Package Content: 1 vial (30mg)
• Weight:7 grams

Retatrutide 30mg is a research-grade peptide manufactured by Novera Compounds in the United States for use exclusively in controlled laboratory investigations. It is studied as a triple receptor agonist because it simultaneously activates the glucagon receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucose-dependent insulinotropic polypeptide (GIP) receptor — a multi-pathway profile that distinguishes it from single- and dual-receptor agonists commonly evaluated in metabolic and endocrine research.

Among the peptides for weight loss currently investigated in laboratory settings, retatrutide has attracted considerable research interest because its coordinated receptor activity allows scientists to study multiple metabolic pathways simultaneously. It has become a focus of preclinical studies exploring weight regulation, energy expenditure, glucose metabolism, and the underlying mechanisms of type 2 diabetes. The product is supplied as a 30mg lyophilized powder vial and requires reconstitution with BAC water before use in research protocols.

Novera Compounds is an independent, United States-based manufacturer that produces this peptide to controlled research standards for laboratory applications. This product is a generic laboratory reagent and has no affiliation with Eli Lilly’s retatrutide pharmaceutical development program; clinical trial findings published in relation to that program should not be interpreted as evidence of safety, efficacy, or suitability for any use of this research-grade material. The Retatrutide peptide 30mg dosage listed on the vial identifies the quantity of lyophilized peptide supplied and is not a dosing recommendation for any application. Retatrutide 30mg is NOT approved for clinical use, human injection, ingestion, therapeutic application, or any other form of human consumption.

Retatrutide’s research profile centers on its classification as a triple receptor agonist, engaging three distinct metabolic signaling pathways concurrently rather than targeting a single receptor.

• Glucagon receptor activation: Studied in relation to glucose output and lipolysis — pathways relevant to energy expenditure and weight-loss research models.
• GLP-1 receptor agonism: Associated with modulation of satiety and energy expenditure signaling, consistent with the broader GLP-1 receptor agonist research literature and central to the weight-reduction focus of most retatrutide study designs.
• GIP receptor activation: Contributes to the regulation of glucose homeostasis and is particularly relevant to research on the pathophysiology of type 2 diabetes.

Advancing Clinical Development Context

While initial Phase 2 data demonstrated distinct metabolic effects from concurrent activation of all three receptors [1], retatrutide has since advanced into extensive Phase 3 clinical evaluations — including the TRIUMPH clinical program — to further characterize its triple-agonist profile [3]. These findings pertain exclusively to Eli Lilly’s investigational pharmaceutical program and should not be attributed to or interpreted as validation of Novera Compounds’ independently manufactured research reagent, which carries no approved therapeutic indication.

This combined mechanism is the primary reason retatrutide is studied as a distinct research category from dual GLP-1/GIP agonists. Researchers continue to evaluate receptor selectivity, intracellular signaling downstream of each pathway, and cumulative metabolic effects using receptor-binding assays, signaling studies, and concentration-response analyses.

Retatrutide is widely investigated in metabolic and endocrine research for its ability to simultaneously activate the GLP-1, GIP, and glucagon receptor pathways. Its triple-agonist profile allows researchers to examine interconnected mechanisms involved in energy regulation, glucose metabolism, and body weight in controlled laboratory settings. Published studies have evaluated the molecule in obesity and type 2 diabetes research contexts, examining effects on body weight, glycemic measures, and metabolic biomarkers [1][2]. These findings relate to investigational clinical research conducted under regulated conditions and should not be interpreted as evidence of clinical or therapeutic efficacy for this research-grade product.

In laboratory settings, retatrutide is used to investigate receptor pharmacology, hormone signaling, and metabolic regulation. Researchers compare its triple-receptor agonist profile with single- or dual-receptor agonist profiles to assess differences in receptor activation, intracellular signaling, and downstream physiological responses [3].

Primary areas of scientific investigation include:

• Weight loss and weight reduction mechanisms
• Metabolic signaling and glucose homeostasis
• Glucagon receptor activation and lipid metabolism
• Energy expenditure and substrate utilization
• Type 2 diabetes pathophysiology
• Comparative receptor agonist pharmacodynamics
• Cellular signaling and biomarker analysis

Research objectives, peptide concentration, study duration, and analytical methods must be determined by qualified investigators in accordance with validated laboratory protocols. Researchers should review product documentation and intended-use restrictions before incorporating any peptide material into laboratory studies.

Retatrutide 30mg is intended strictly for in vitro research ONLY and is NOT approved for human use, clinical applications, or human consumption.

Retatrutide 30mg is supplied as a lyophilized (freeze-dried) powder and requires reconstitution with BAC water (bacteriostatic water) before use in a research protocol. Bacteriostatic water is a sterile, non-pyrogenic preserved solution containing 0.9% benzyl alcohol, manufactured to support multiple withdrawals from a single vial over an extended period.

How Much BAC Water to Reconstitute 30mg Retatrutide

The appropriate volume is not fixed — it depends entirely on the target concentration (mg/mL) required for the specific experimental design. Researchers should calculate the volume based on their desired final concentration rather than relying on a universal dilution ratio.

A typical reconstitution range is 5–10 mL of BAC water per 30mg vial, though the optimal volume of BAC water for 30mg Retatrutide will vary according to the intended concentration and study protocol. During Retatrutide 30mg reconstitution, BAC water should be introduced slowly along the inside wall of the vial, and the contents gently swirled — not shaken — to help preserve peptide integrity. These represent common peptide-handling practices and should not be interpreted as manufacturer instructions.

After reconstitution, the solution should be stored refrigerated at 2–8°C. Researchers asking how long 30mg of retatrutide lasts should consult the available product documentation and confirm stability parameters against the manufacturer’s batch records, as storage duration depends on the reconstitution method, handling conditions, and institutional procedures.

Retatrutide 30mg is designated for use by qualified laboratory personnel only and must be handled in accordance with the institutional safety procedures applicable to peptide research materials. It is intended strictly for in vitro research and must not be represented as a pharmaceutical product or used for clinical application, patient treatment, or human consumption in any form.

• Research-only status: This product is intended exclusively for in vitro and preclinical laboratory research. It is NOT approved for human injection, ingestion, or any form of therapeutic or clinical exposure.
• Regulatory restriction: Any use outside controlled laboratory research is unauthorized and outside the product’s intended and legal scope.
• Research-grade manufacturing: This peptide is manufactured to research-grade standards. It is not validated or labeled as a pharmaceutical or therapeutic product.
• Handling protocol: Handle as a laboratory research chemical and follow all institutional safety procedures for peptide storage, labeling, and disposal.
• No human safety data: Side effects of retatrutide in humans are unknown for this research-grade material. Any adverse event information from published literature refers exclusively to investigational clinical trials conducted under regulated conditions, not to this product.

Adherence to these standards supports research integrity and ensures the product is used only within its intended laboratory context.

Retatrutide 30mg is classified as a research-grade peptide intended exclusively for scientific investigation in qualified laboratory settings. Researchers and institutions are responsible for ensuring that acquisition, handling, and use of this material comply with all applicable regulations and institutional policies governing research compounds.

• Research-only product: Retatrutide 30mg is intended solely for in vitro and preclinical research. It has not been approved for human use by the FDA, EMA, or any other regulatory authority.
• Explicit use restriction: This product is designated exclusively for laboratory research and is NOT intended for human injection, ingestion, therapeutic application, or any other clinical use.
• Manufacturer information: Novera Compounds is an independent, United States-based manufacturer that produces this research-grade peptide to laboratory standards. It is supplied without pharmaceutical or clinical labeling and is in no way affiliated with Eli Lilly’s clinical retatrutide development program.
• No regulatory approval: Retatrutide has not received regulatory approval for therapeutic or clinical indications from the FDA, EMA, or other major health authorities.
• Licensed use only: Supply is intended for qualified researchers, research institutions, and laboratories conducting legitimate scientific investigations.

Retatrutide remains an investigational compound under active clinical development. Researchers and institutions are responsible for independently verifying current regional regulations and institutional guidelines before procurement.

Access to research-grade retatrutide is restricted to qualified professionals operating within permitted research contexts. When buying research peptides, professionals should prioritize verifiable purity documentation, LOT number traceability, and a certificate of analysis from the supplying laboratory.

Maylips connects licensed researchers and institutions with sourcing guidance and documentation support related to verified research-grade suppliers. Qualified professionals looking to buy Retatrutide 30mg online for legitimate laboratory purposes are encouraged to contact the Maylips support team for assistance with sourcing documentation and supplier information.

Institutions can also check for wholesale buying options, and those interested in buying Retatrutide wholesale for eligible research programs are welcome to reach out to the Maylips support team directly.

[1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023. https://doi.org/10.1056/nejmoa2301972

[2] Sanyal AJ, Kaplan LM, Frias JP, et al. Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Phase 2A Trial. Nature Medicine. 2024. https://doi.org/10.1038/s41591-024-03018-2

[3] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025. https://doi.org/10.3390/biom15060796